Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557372 · ClinicalTrials.gov registry record · NA
Mathematical Model-Adapted Radiation In Glioblastoma
A NA study of Recurrent Glioblastoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT03557372: Completed NA study of Recurrent Glioblastoma, sponsored by Dana-Farber Cancer Institute.
NCT03557372 is a NA study of Recurrent Glioblastoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 14 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03557372, a NA study of Recurrent Glioblastoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma. The name of the radiation schedule involved in this study is: \- Re-irradiation for glioblastoma using a novel Mathematical Model-Adapted Radiation Fractionation Schedule
Primary Outcome
Successful completion of radiotherapy is defined as receipt of all scheduled fractions of daily radiotherapy within 24 hours of once daily fractions and within 1 hour of three-times daily fractions.
Conditions Studied
Interventions
- RADIATION Mathematical Model-Adapted Radiation Fractionation Schedule
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2022-11-09 |
| Phase | NA |
What the finished NCT03557372 record still lists
NCT03557372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Mathematical Model-Adapted Radiation Fractionation Schedule is the first listed.
NCT03557372 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03557372 about?
NCT03557372 is a clinical study titled "Mathematical Model-Adapted Radiation In Glioblastoma". This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma. The name of the radiation schedule involved in this study is: \- Re-i...
What is the current status of trial NCT03557372?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-11-12. Estimated completion is 2022-11-09.
What conditions does trial NCT03557372 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT03557372?
The interventions under investigation include: Mathematical Model-Adapted Radiation Fractionation Schedule (RADIATION).
Who is sponsoring clinical trial NCT03557372?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03557372 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03557372's enrollment target sits among peer trials
14 52nd of 62 higher than 8 of 62 other Recurrent Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
RECRUITING · NA
-
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
RECRUITING · NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
RECRUITING · NA
-
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
ACTIVE NOT RECRUITING · NA
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy